Vaxart, Inc. (VXRT)
VXRT is quoted over the counter, not listed on an exchange. Vaxart, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | VXRT, quoted over the counter |
| SEC CIK | 0000072444 |
| OTC Markets tier | OTCQX (price source, 2026-11-13) |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Business address | South San Francisco, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the date of the issuance of these unaudited condensed consolidated financial statements." | 10-Q 2026-11-05 |
| Cash and burn | $35.1M cash; operating cash flow $8.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 243,702,034 (2026-10-30); 240,069,844 a year earlier; 152,038,840 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-05-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-11-21 |
| Auditor | WithumSmith+Brown, PC, San Francisco, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $31K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $10.6M | -$17.7M | $1.4M | $35.1M | No debt tags | $181.3M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $27.2M | -$13.5M | $2.8M | $50.9M | No debt tags | $243.1M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $39.2M | $5.2M | -$2.1M | $50.7M | No debt tags | $255.6M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $104.2M | $55.0M | $30.7M | $53.8M | No debt tags | $237.3M | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | $72.4M | -$8.1M | $2.6M | $16.9M | No debt tags | $148.2M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $39.7M | -$15.0M | -$15.9M | $20.1M | No debt tags | $80.7M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $20.9M | -$15.6M | -$9.6M | $28.7M | No debt tags | $47.4M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $15.2M | -$12.0M | -$7.3M | $25.2M | No debt tags | $28.7M | 10-K 2026-03-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-05-19 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-07-06 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier